105 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
attributed to the increased sales of lower cost dosages of AYVAKIT/AYVAKIT.
R&D Expenses: Research and development expenses were $88.2 million … our portfolio as we execute across our top priority programs and the timing of manufacturing of clinical trial materials. Research and development
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
15 Feb 24
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
7:05am
was mainly due to a decrease in inventory write-downs and the cost of collaboration-related sales.
R&D Expenses: Research and development expenses were … of clinical trial materials. Research and development expenses also included $10.0 million in stock-based compensation expenses for the fourth quarter
8-K
EX-99.1
tnl3h
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
8-K
EX-99.1
4hccjaqurm xsse
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.1
9sblxt0qt chpgnh94t
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
hvci11txscpqu7zck1p
4 May 23
Blueprint Medicines Reports First Quarter 2023 Results
7:18am
8-K
EX-99.2
athjl0dmm
1 Nov 22
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale
8:08am
8-K
EX-99.1
45i5btkq4dxxcd
1 Nov 22
Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale
8:08am
8-K
EX-99.1
tpspgi4jyobi8t5nab8d
2 Aug 22
Blueprint Medicines Reports Second Quarter 2022 Results
7:47am